Medical Diet
Medical Diet (Self-Pay Treatment) Information
"A Medical Diet Without Effort?
— No. Relying Solely on Medication Is a Recipe for Rebound."
— No. Relying Solely on Medication Is a Recipe for Rebound."
Modern society fuels our cravings for food and pressures us with appearance-based competition.
Are you being led to believe that weight loss can be achieved just by taking medication?
Healthy dieting is simple—but not so simple that medication alone can achieve it.
The idea that spending money on weight loss medication or gym memberships will guarantee beauty and health is an illusion created by the consumer culture.
Are you being led to believe that weight loss can be achieved just by taking medication?
Healthy dieting is simple—but not so simple that medication alone can achieve it.
The idea that spending money on weight loss medication or gym memberships will guarantee beauty and health is an illusion created by the consumer culture.
To see through misleading information, it's essential to have a calm, reliable guide by your side.
Balanced meals. Moderate exercise.
We support your efforts to improve your eating and exercise behavior with medical supervision and a once-weekly self-injection of Mounjaro.
We'll carefully guide you on how to reduce side effects and prevent rebound, walking with you all the way as your personal physician.
The real "rebound prevention" in medical dieting is receiving proper guidance from your trusted doctor.
(Please note: There are exaggerated rumors circulating on social media about the effects and side effects of Mounjaro.
Combining Mounjaro with other weight-loss drugs can be dangerous.
Reselling prescription medications without proper qualifications is a criminal offense. )
Balanced meals. Moderate exercise.
We support your efforts to improve your eating and exercise behavior with medical supervision and a once-weekly self-injection of Mounjaro.
We'll carefully guide you on how to reduce side effects and prevent rebound, walking with you all the way as your personal physician.
The real "rebound prevention" in medical dieting is receiving proper guidance from your trusted doctor.
(Please note: There are exaggerated rumors circulating on social media about the effects and side effects of Mounjaro.
Combining Mounjaro with other weight-loss drugs can be dangerous.
Reselling prescription medications without proper qualifications is a criminal offense. )
This program is intended for individuals with a BMI of 25 or higher.
Calculation formula: Weight (kg) ÷ (Height (m))² = BMI
Example for a BMI of 25:
Example for a BMI of 25:
- For a height of 150 cm,1.5 × 1.5 × 25 = 56 kg
- For a height of 160 cm: 1.6 × 1.6 × 25 = 64 kg
- For a height of 170 cm: 1.7 × 1.7 × 25 = 72 kg
- For a height of 180 cm: 1.8 × 1.8 × 25 = 81 kg
Precautions
- The appropriate target weight for weight loss will be determined individually in consultation with a physician.
- In-person consultations only. Online consultations are not currently available.
- Please bring any prior health examination results with you if possible.
- For those who wish, we can perform a health examination including a diabetes test for 5,000 yen (tax included) or a liver function, lipid, and diabetes test for 10,000 yen (tax included), and explain the results on the spot. If diabetes is diagnosed, Mounjaro may be prescribed under health insurance coverage at a later date.
Option
【Health Checkup(Blood test)】
Diabetes Test 5,000 yen (tax included)
or Liver Function, Lipid, and Diabetes Test 10,000 yen (tax included)
Diabetes Test 5,000 yen (tax included)
or Liver Function, Lipid, and Diabetes Test 10,000 yen (tax included)
Pricelist
Fees for Medical Dieting(2 weeks trial)
※Trial use is only for once.
| 【First 2 weeks trial】 | |
| Initial consultation fee | 1,100 |
| Initial checkup fee | 2,200 |
| MOUNJARO 2.5mg 2 injections | 11,000 （￥5,500/week） |
| Total ¥14,300(tax incl.) | |
Fees for Medical Dieting(4 weeks)
| 【First 4 weeks】 | |
| Initial consultation fee | 1,100 |
| Initial checkup fee | 2,200 |
| MOUNJARO 2.5mg 4 injections | 19,800 （￥4,950/week） |
| Total ￥23,100(tax incl.) | |
| 【From the 2nd visit (continuing with 2.5mg)】 | |
| Re-consultation fee | 1,100 |
| MOUNJARO 2.5mg 4 injections | 19,800 （￥4,950//week） |
| Total ￥20,900(tax incl.) | |
| 【From the 2nd visit】 | |
| Re-consultation fee | 1,100 |
| MOUNJARO 5mg 4 injections | 29,700 （￥7,425/week） |
| Total ￥30,800(tax incl.) | |
| 【From the 3rd visit】 | |
| Re-consultation fee | 1,100 |
| MOUNJARO 7.5mg 4 times （2 injections at one time: one 5 mg injection and one 2.5 mg injection.） |
39,600 （￥9,900/week） |
| Total ￥40,700(tax incl.) |
|
| 【From the 4th visit】 | |
| Re-consultation fee | 1,100 |
| MOUNJARO 10mg 4 times （Two 5mg injections at one time） |
49,500 （￥12,315/week） |
| Total ￥50,600(tax incl.) | |
MOUNJARO
Who is recommended for Mounjaro?
- Those who find it difficult to continue a diet on their own
- Those concerned about visceral fat
- Those who find it increasingly difficult to lose weight as they age
- Those experiencing knee or back pain due to weight
Who should not use Mounjaro?
- Pregnant or breastfeeding women.
- Those with a history of acute pancreatitis, intestinal obstruction, or thyroid cancer,and those with a personal or family history of multiple endocrine neoplasia syndrome.
- Those under 18 years of age (minors).
- Those who are underweight.
Those who require caution when using Mounjaro:
- Those currently taking diabetes medications may experience enhanced blood sugar-lowering effects. (※We recommend health insurance-covered treatment rather than self-pay treatment.)
- The effectiveness of oral contraceptives may be reduced.
- The effectiveness of warfarin may be enhanced.
Mounjaro’s Effects
3 Key Benefits for Weight Management
Appetite Suppression
Mounjaro works by mimicking natural hormones (GIP and GLP-1) that regulate appetite in the brain.
This leads to a reduced sensation of hunger, making it easier to eat less without constant cravings.
Mounjaro works by mimicking natural hormones (GIP and GLP-1) that regulate appetite in the brain.
This leads to a reduced sensation of hunger, making it easier to eat less without constant cravings.
Prolonged Satiety
In addition to curbing hunger, Mounjaro slows gastric emptying—the rate at which food leaves your stomach.
This helps you feel fuller for longer after meals, reducing the urge to snack or overeat.
In addition to curbing hunger, Mounjaro slows gastric emptying—the rate at which food leaves your stomach.
This helps you feel fuller for longer after meals, reducing the urge to snack or overeat.
Enhanced Fat Burning
Mounjaro also improves metabolic function, promoting the body’s ability to burn stored fat for energy.
It increases insulin sensitivity and supports a shift from fat storage to fat utilization.
Mounjaro also improves metabolic function, promoting the body’s ability to burn stored fat for energy.
It increases insulin sensitivity and supports a shift from fat storage to fat utilization.
*Tirzepatide=Mounjaro
From the SURMOUNT-1 trial
From the SURMOUNT-1 trial
Dosage, Goal Setting, and Treatment Duration
In overseas clinical trials (SURMOUNT-1), participants with an average body weight of 105 kg began treatment with 2.5 mg of the medication for the first 4 weeks, then increased to 5 mg. Over the course of 18 months, they achieved an average weight loss of 16%—from 105 kg down to 88 kg.
At our clinic, we’ve seen that many individuals weighing between 60 and 80 kg continue to lose weight steadily while staying on the initial 2.5 mg dose for more than four weeks. As long as progress is evident, we aim to maintain this lower dose to minimize medication exposure. For those over 90 kg, however, an increase to 5 mg or higher is often necessary to see continued results.
The goal of treatment is not just weight loss, but to use the support of Mounjaro to reset lifestyle habits—particularly in diet and exercise—while gradually working toward a healthy, sustainable weight. Ideally, patients aim to find their own best weight within the BMI range of approximately 22–24, though this varies by individual. Ultimately, the real goal isn’t a number on the scale, but long-term health and well-being, sustained without relying on medication.
Some patients may complete treatment in as little as 3 months, but most can expect around 6 months (24 weeks) as a standard timeframe. Those starting at a higher weight may require longer. A typical healthy pace of weight loss is about 0.5 to 1 kg per week. If progress is slow, we may consider increasing the dose or adjusting lifestyle strategies. If weight is dropping too quickly, we’ll assess whether there is concern over muscle loss or whether the patient is maintaining strength through regular resistance training. Monthly check-ups allow us to review progress and make decisions together between patient and physician.
At our clinic, we’ve seen that many individuals weighing between 60 and 80 kg continue to lose weight steadily while staying on the initial 2.5 mg dose for more than four weeks. As long as progress is evident, we aim to maintain this lower dose to minimize medication exposure. For those over 90 kg, however, an increase to 5 mg or higher is often necessary to see continued results.
The goal of treatment is not just weight loss, but to use the support of Mounjaro to reset lifestyle habits—particularly in diet and exercise—while gradually working toward a healthy, sustainable weight. Ideally, patients aim to find their own best weight within the BMI range of approximately 22–24, though this varies by individual. Ultimately, the real goal isn’t a number on the scale, but long-term health and well-being, sustained without relying on medication.
Some patients may complete treatment in as little as 3 months, but most can expect around 6 months (24 weeks) as a standard timeframe. Those starting at a higher weight may require longer. A typical healthy pace of weight loss is about 0.5 to 1 kg per week. If progress is slow, we may consider increasing the dose or adjusting lifestyle strategies. If weight is dropping too quickly, we’ll assess whether there is concern over muscle loss or whether the patient is maintaining strength through regular resistance training. Monthly check-ups allow us to review progress and make decisions together between patient and physician.
About Rebound Weight Gain
What happens to your body when you stop taking weight-loss drugs l GMA(ABC)
When we interview patients who had been prescribed Mounjaro through online consultations, we often hear the same story: they lost weight temporarily while using Mounjaro, but as soon as they stopped taking it, they regained all the weight. It seems that in many of these online consultations, there was little to no guidance provided on how to prevent rebound weight gain.
Rebound is a known issue, even with bariatric surgery or GLP-1 receptor agonists like Wegovy. So what is necessary to avoid rebound?
In a recent international clinical trial (SURMOUNT-4), a group with an average weight of 107 kg received Mounjaro (5 mg or 10 mg) for 36 weeks, resulting in a 21% reduction in body weight (107 kg → 85 kg). Then, while continuing basic dietary and exercise guidance, the medication was secretly switched to a placebo. One year later (52 weeks later), some weight had been regained, and after a total of 1 year and 9 months, the group had an average weight loss of just 9.9% (107 kg → 96 kg). Only 16.6% of the placebo group were able to avoid rebound weight gain.
To avoid rebound, several strategies can be considered:
1)Continuing Mounjaro
2)Switching from Mounjaro to an alternative medication
3)Gradually tapering Mounjaro or spacing out injections before discontinuation
4)Strengthening dietary and exercise therapy
Rebound is a known issue, even with bariatric surgery or GLP-1 receptor agonists like Wegovy. So what is necessary to avoid rebound?
In a recent international clinical trial (SURMOUNT-4), a group with an average weight of 107 kg received Mounjaro (5 mg or 10 mg) for 36 weeks, resulting in a 21% reduction in body weight (107 kg → 85 kg). Then, while continuing basic dietary and exercise guidance, the medication was secretly switched to a placebo. One year later (52 weeks later), some weight had been regained, and after a total of 1 year and 9 months, the group had an average weight loss of just 9.9% (107 kg → 96 kg). Only 16.6% of the placebo group were able to avoid rebound weight gain.
To avoid rebound, several strategies can be considered:
1)Continuing Mounjaro
2)Switching from Mounjaro to an alternative medication
3)Gradually tapering Mounjaro or spacing out injections before discontinuation
4)Strengthening dietary and exercise therapy
In clinical trials, patients did not know whether they were switched to a placebo, so they couldn't fully grasp the real risk of rebound. In real life, however, patients are aware of this possibility and can take active steps to prevent it.
At our clinic, from the very beginning of Mounjaro treatment, we provide guidance on developing balanced eating habits and healthy exercise routines to help patients overcome the expected rebound phase. Depending on the individual, we may recommend continuing Mounjaro, tapering the dosage, or adjusting the injection intervals.
At our clinic, from the very beginning of Mounjaro treatment, we provide guidance on developing balanced eating habits and healthy exercise routines to help patients overcome the expected rebound phase. Depending on the individual, we may recommend continuing Mounjaro, tapering the dosage, or adjusting the injection intervals.
We estimate muscle mass and body fat percentage using a body composition analyzer.
About Side Effects
It's important to note that the clinical trials were conducted under quite aggressive conditions—for example, participants had an average body weight of over 100 kg, and the dosage was increased rapidly according to a fixed schedule. As such, even minor and tolerable side effects, as well as extremely rare ones, were carefully documented.
In our actual clinical experience, more than half of patients report no side effects other than appetite suppression. Among the remaining patients who do experience side effects, the most common complaint is a tolerable "queasy" feeling in the stomach or a sense of heaviness in the chest for 2–3 days after the injection. Most patients say, “It’s not a big deal compared to the benefit of losing weight.”
However, for individuals with more sensitive gastrointestinal systems, symptoms such as nausea, vomiting, or aversion to food smells—similar to morning sickness—may occur. These symptoms are typically temporary and can often be avoided or minimized by paying attention to eating habits, especially during the early phase of treatment or when increasing the dosage.
Pancreatitis, gallstones, and cholecystitis are in fact rare, but if any concerning symptoms arise, we can immediately evaluate them at our clinic with blood tests, ultrasound, or CT scans. As for the links to thyroid cancer or multiple endocrine neoplasia syndrome reported in animal studies, these remain only theoretical risks in humans.
Although acute pancreatitis is a serious condition if it occurs, the risk has not been clearly established with Mounjaro, unlike the very rare cases reported with earlier GLP-1 receptor agonists such as Victoza and Ozempic.
Hypoglycemia is unlikely at lower doses such as 2.5 mg or 5 mg, and is considered rare unless the patient is also taking other glucose-lowering medications or engaging in extreme fasting.
In our actual clinical experience, more than half of patients report no side effects other than appetite suppression. Among the remaining patients who do experience side effects, the most common complaint is a tolerable "queasy" feeling in the stomach or a sense of heaviness in the chest for 2–3 days after the injection. Most patients say, “It’s not a big deal compared to the benefit of losing weight.”
However, for individuals with more sensitive gastrointestinal systems, symptoms such as nausea, vomiting, or aversion to food smells—similar to morning sickness—may occur. These symptoms are typically temporary and can often be avoided or minimized by paying attention to eating habits, especially during the early phase of treatment or when increasing the dosage.
Pancreatitis, gallstones, and cholecystitis are in fact rare, but if any concerning symptoms arise, we can immediately evaluate them at our clinic with blood tests, ultrasound, or CT scans. As for the links to thyroid cancer or multiple endocrine neoplasia syndrome reported in animal studies, these remain only theoretical risks in humans.
Although acute pancreatitis is a serious condition if it occurs, the risk has not been clearly established with Mounjaro, unlike the very rare cases reported with earlier GLP-1 receptor agonists such as Victoza and Ozempic.
Hypoglycemia is unlikely at lower doses such as 2.5 mg or 5 mg, and is considered rare unless the patient is also taking other glucose-lowering medications or engaging in extreme fasting.
Our Approach to Medical Diet Guidance
At our clinic, we provide guidance based on the following perspectives:
1.Cognitive Behavioral Therapy (CBT)
2.Exercise and Nutrition Science
3.Chrono-nutrition Science(about timing of nutrition intake)
4.Cerebral Physiology(about hormonal set-point)
5.Prevention of Weight Regain, Sarcopenic Obesity, and Osteoporosis
We offer comprehensive support incorporating all five of these elements.
1.Cognitive Behavioral Therapy (CBT)
2.Exercise and Nutrition Science
3.Chrono-nutrition Science(about timing of nutrition intake)
4.Cerebral Physiology(about hormonal set-point)
5.Prevention of Weight Regain, Sarcopenic Obesity, and Osteoporosis
We offer comprehensive support incorporating all five of these elements.
Notification Based on Medical Advertising Guidelines
①Unapproved Pharmaceuticals (Off-label Use)
Mounjaro is approved by the Ministry of Health, Labour and Welfare (MHLW) as a treatment for type 2 diabetes. It is not approved for obesity treatment in Japan.
②Procurement Route
The Mounjaro prescribed at our clinic is obtained through a domestic pharmaceutical distributor.
③Availability of Approved Drugs in Japan
In Japan, a medication with the same active ingredient has been approved for obesity treatment under the name “Zepbound,” and optimal use promotion guidelines have been established.
④Safety Information in Foreign Countries
Mounjaro has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.
⑤In the Case of Serious Side Effects
If serious adverse effects occur, the national relief systems for drug-related injuries or infections caused by biological products will not apply.
⑥Efficacy and Safety
Efficacy and safety are described on this page.
⑦Individual Differences in Effectiveness
The degree of treatment effectiveness varies by individual.
①Unapproved Pharmaceuticals (Off-label Use)
Mounjaro is approved by the Ministry of Health, Labour and Welfare (MHLW) as a treatment for type 2 diabetes. It is not approved for obesity treatment in Japan.
②Procurement Route
The Mounjaro prescribed at our clinic is obtained through a domestic pharmaceutical distributor.
③Availability of Approved Drugs in Japan
In Japan, a medication with the same active ingredient has been approved for obesity treatment under the name “Zepbound,” and optimal use promotion guidelines have been established.
④Safety Information in Foreign Countries
Mounjaro has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes.
⑤In the Case of Serious Side Effects
If serious adverse effects occur, the national relief systems for drug-related injuries or infections caused by biological products will not apply.
⑥Efficacy and Safety
Efficacy and safety are described on this page.
⑦Individual Differences in Effectiveness
The degree of treatment effectiveness varies by individual.
